CD274 and urinary bladder carcinoma: First-line anti-PD-L1 therapy was European Medicines Agency (EMA)-approved for bladder cancer with CPS ≥ 10 (Pembrolizumab) or IC ≥ 2 (5%, Azetolizumab).